Delivery Order SPE2DB22D3016-SPE2DB26FAAX5
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $7,871.74 for XELJANZ XR 11 mg tablets (30-count units) on September 12, 2025, with completion expected by September 15, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. XELJANZ XR is a branded immunosuppressant medication used in the treatment of...
- The Defense Logistics Agency awarded a delivery order valued at $14,401.37 to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) on June 26, 2025, with completion scheduled for June 27, 2025. This firm fixed-price delivery order represents a non-competitive set-aside transaction and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. XELJANZ XR is a prescription immunosuppressant medication used to treat rheumatoid arthritis and...
- The Defense Logistics Agency awarded a delivery order valued at $5,451.63 to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-unit packages) on August 7, 2025, with an ultimate completion date of August 8, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. XELJANZ XR is a prescription medication used to treat rheumatoid arthritis and other...
- The Defense Logistics Agency awarded a delivery order valued at $71,664.37 to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) on October 23, 2025, with an ultimate completion date of October 24, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. XELJANZ XR is a prescription immunosuppressant medication used to treat rheumatoid arthritis and...
- The Defense Logistics Agency awarded a delivery order valued at $2,864.37 to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of XELJANZ XR 11 mg tablets in quantities of 30 units. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under open competition. The contract calls for delivery to be completed by August 1, 2025, with performance taking place at the vendor's corporate office location in Conshohocken, Pennsylvania. XELJANZ XR is a...
- The Defense Logistics Agency awarded a delivery order valued at $3,565.45 to AmerisourceBergen Drug Corp for XELJANZ XR 11 MG tablets (30-count units) on September 3, 2025, with completion scheduled for September 4, 2025. This competitively awarded, firm fixed-price delivery order was issued without a set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. XELJANZ XR is a prescription medication used to treat inflammatory conditions, reflecting the...
- The Defense Logistics Agency awarded a delivery order valued at $27,184.05 to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) on July 22, 2025, with an ultimate completion date of July 23, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is classified as a child contract. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate headquarters. XELJANZ XR is a...
- The Defense Logistics Agency awarded a $11,537.39 firm fixed-price delivery order to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) on July 1, 2025, with completion targeted for July 2, 2025. This non-set-aside, competitively awarded contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The pharmaceutical distributor, headquartered...
- The Defense Logistics Agency awarded a delivery order valued at $5,053.83 to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) on August 11, 2025, with an ultimate completion date of August 12, 2025. This firm fixed-price, competitively awarded delivery order represents a routine pharmaceutical procurement under the company's existing contract vehicle with DLA. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,198.50 to AmerisourceBergen Drug Corp for the supply of XELJANZ XR 11 mg tablets (30-count units). This firm fixed price, non-set-aside delivery order was awarded on August 20, 2025, with an ultimate completion date of August 21, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. XELJANZ XR is a prescription immunosuppressant medication used to treat rheumatoid arthritis...
- SPE2DB22D3016Indefinite Delivery Contract
- SPE2DB22D3016-SPE2DB26FAAX5Delivery Order
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $17,910.83 for XELJANZ XR 11 MG tablets (30-count units) on October 30, 2025, with an ultimate completion date of October 31, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. XELJANZ XR is a prescription medication used primarily for the treatment of rheumatoid arthritis and other inflammatory conditions. This delivery order represents a task order issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor and critical vendor for federal medical procurement, AmerisourceBergen Drug Corp supplies a comprehensive portfolio of medications and medical supplies to support military healthcare programs worldwide, including the Defense Health Agency and U.S. Coast Guard. The company's performance under its prime IDC demonstrates its capability to fulfill federal pharmaceutical supply requirements across multiple therapeutic domains through open competition.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $17.9k | 10/30/25 |